This chapter summarizes available methods for the preparation of synthetic vaccines based on glycopeptides and recent advances in this field. It further includes results of their immunological evaluation. Syntheses of glycopeptides of defined chemical structure and conjugation of these compounds to a carrier protein or an immunostimulant are of interest for the development of new immunotherapeutics and/or antibody-based diagnostics. Since a number of years, the aberrant glycosylation of the tumorassociated mucin MUC1 forming tumor specific epitopes on the epithelial cell surface has been considered an attractive research target for the preparation of such vaccines. Examples of synthetic vaccines directed against the O-glycosylated MUC1 tandem repeats will here be given including synthetic MUC1 glycopeptides conjugated to a T-cell epitope peptide, to a carrier protein, to a lipid immunostimulant or the multimeric presentation of glycopeptides on dendrimers. Other attractive targets for immunotherapy are the viral envelope proteins HIV gp120 and HIV gp41 , which are highly glycosylated with high-mannose and complex type Nglycans. Examples will be given, which illustrate syntheses of high-mannose HIV gp120 or gp41 glycopeptides with the natural peptide backbone or with a nonnatural cyclic backbone to mimic the high-mannose cluster domain of HIV gp120. In addition the synthesis and immunological evaluation of a vaccine will be described, which contains the high-mannose cluster mimotope glycopeptide conjugated to an outer membrane protein complex (OMPC) as the carrier.
Introduction
In multi-cellular organisms, many proteins are co-or posttranslationally modified by mono-or oligosaccharides. It has become evident that these glycoproteins play important roles in diverse biochemical processes. The saccharides influence the physiochemical properties, which includes conformational effects on the protein, the stability against proteolysis, or the lubrication of cells. In addition, the glycans are involved in cell-cell recognition and cell-external agent interactions. These interactions induce biological events, which are involved in cell-growth and differentiation, cellproliferation, cell-adhesion, binding of pathogens, fertilization and immune responses. [1] [2] [3] [4] [5] [6] The glycans assist in protein folding and transport, they are involved in pathogenic processes like chronic inflammation, 5 viral and bacterial infections, [7] [8] [9] [10] tumor growth and metastasis 11, 12 and auto-immune disorders. 13, 14 The variety of events affected by protein glycosylation is not surprising. Carbohydrates are unique in their complexity of structure. In contrast to oligonucleotides and proteins, they can be connected in more than one form: connected via different configural positions of the glycan residue and also via an anomeric a or b glycosidic linkage. The different modes of connections can lead to long linear or highly branched saccharide structures. By combining different types of glycans like galactose, glucose, N-acetylgalactosamine, N-acetylglucosamine, fucose, mannose, sialic acid and others, an enormous variety of combinations can be formed. Nature is only using a small portion of these possible combinations. The biosyntheses of different oligosaccharides are dependent on glycosyltransferases which are gene-encoded. Each type of connection and glycan residue needs a specific enzyme. Of practical reasons this restricts the number of combinations. Nature also limits the number of final products that can be made by having common core structures. The saccharides can be linked to the protein backbone via an O-glycoside bond or via N-glycosyl amide bond in N-glycoproteins. In the most common type of O-glycoproteins, the mucin type, a GalNAc residue is connected to the protein backbone via an O-glycosidic linkage to serine or threonine. 15 The GalNAc residue can be further extended with additional Gal, GlcNAc or GalNAc residues forming the core structures 1-8. These core structures can then be extended with one or repeated type 1 (Gal b1-3 GlcNAc) or type 2 (Gal b1-4 GlcNAc) glycosylation and terminated with fucose, sialic acid and/or GalNAc residues leading to complex saccharides (Fig. 1a, b) .
The majority of N-glycoproteins have a common pentasaccharide core consisting of three mannoses and two GlcNAc residues, one of the GlcNAc residues is linked to the protein core via an amide bond of an aspargine side chain. The pentasaccharide core structure can be additionally extended forming high mannose type, hybrid type or complex type N-glycoproteins 16 ( Fig. 1c, d ). In spite of the restrictions made by nature when forming complex oligosaccharide structures, a large amount of combinations can be formed, and since the majority of glycans are attached to other molecules like proteins or lipids, an additional dimension of complexity results. To understand the function and relevance of saccharides, it is important to also consider the backbone to which it is connected. In case of glycoproteins, it is often the effect of glycosylation on the protein backbone that is interesting to study in terms of conformational or proteolytic stability, structure recognition, binding or multimeric effects. Since glycans are not direct gene products, they are formed in an environment of competing glycosyltransferases and glycosidases with variations in substrate and donor levels. This results in the microheterogeneity of the glyoproteins.
Therefore, it is problematic to study glycosylation only by gene expression studies on enzyme levels or by investigations of isolated glycoproteins. It is also difficult to isolate pure glycoproteins in sufficient quantities. By synthetic methods, glycopeptides with a defined structure can be produced. These peptides can be employed to study conformational effects of glycosylation, 17 binding events to cell-adhesion molecules 18 or pathogens or for the construction of vaccines or the production of inhibitors mainly in form of glycopeptide mimics. Synthetic glycopeptides can be ligated to proteins forming homogeneously glycosylated proteins, 19 which might be useful for studying glycosylation and for applications in therapy. In this chapter, recent advances in the synthesis of vaccines based on glycopeptides and their immunological evaluation will be described. So far, the aberrant glycosylation of mucin (MUC1) glycoproteins has been the major research target concerning the development of glycopeptide vaccines. NGlycosylated epitopes of the HIV-1 envelope glycoproteins gp120 and gp41 are other molecular targets, that have been explored during recent years. Syntheses of glycopeptide vaccines employing various conjugation strategies to different immunostimulants will also be discussed. A specific immune response generated from such vaccines could be valuable in immunotherapy through vaccine or humanised monoclonal antibody treatment. In addition, generated monoclonal antibodies from synthetic vaccines with a high binding specificity would be precious tools in immunodiagnosis. its precursor T N antigen structure. 20 It was also found that monoclonal antibodies generated from these tumor-associated structures showed crossreactivity to the desialylated form of glycophorin A, i.e. asialoglycophorin A. From these studies it could be concluded, that these T-and T N -glycoproteins on the epithelial tumor cells must be structurally related to asialoglycophorin 20 ( Fig. 2a) . Glycophorin A is the major sialoglycoprotein on erythrocytes. In the N-terminal domain it contains cryptic T-antigen structures glycosylated with sialic acid at the 3-position of the galactose and at the 6-position of the GalNac residue.
Synthesis of tumor-associated glycopeptides and glycopeptide vaccines
The glycophorin exists in two blood group specificities, M and N, with identical glycoforms, but different in two of the totally 131 amino acids, one of those is the N-terminal residue which is a serine in blood group M, but a leucine in blood group N. 21 These studies initiated syntheses of glycopeptide vaccines targeting the N-terminal region of asialoglycophorin A 22 (Fig. 2b) . The antibodies generated from a synthetic glycopeptide vaccine based on the N-terminal region of asialoglycophorin A of blood group M were specific to the T-antigen glycan structure and also to the peptide backbone structure differentiating between blood group M and N. This result suggested that both the glycan and peptide backbone structure are relevant for the antibody binding specificity. The generated antibodies showed affinity to epithelial tumor tissues, but also to normal tissues. It could be concluded that the synthesized T-antigen glycopeptide structure is tumorassociated, but not sufficiently tumor-selective. In this context, more recent investigations showed that mucin MUC1 expressed on epithelial cells is a tumor-associated glycoprotein. 23 Mucins constitute a class of extensively glycosylated proteins expressed on the surface of epithelial cells or secreted to function in mucus. They normally carry complex and highly branched O-linked carbohydrate structures that shield the protein core. The membrane bound glycoprotein MUC1 is the most intensively studied mucin protein with regard to cancer immunotherapy. 12, 24 The extracellular domain has a structural feature common to all mucins. It contains a region of a variable number of tandem repeats (VNTR). The repeats have identical or very similar amino acid sequences, which are rich in proline, serine and threonine. In MUC1 from different sources, variable numbers of the tandem repeat were found. The tandem repeat consists of 20 amino acids of the sequence HGVTSAPDTRPAPGSTAPPA 25 which includes five potential O-glycosylation sites (underlined). On epithelial tumor cells, MUC1 is extensively overexpressed and its glycosylation pattern has distinctly been altered. Concomitant down-regulation of glycosyl transferases, in particular the core 2 b-1,6-N-acetylglucosaminyltransferase, and up-regulation of sialyltransferases result in short saccharides often prematurely sialylated. 20, [26] [27] [28] [29] T N , T, Sialyl-T N , (2,3)-Sialyl-T and (2,6)-Sialyl-T structures constitute important examples of such tumor-associated saccharide antigens (Fig. 3) . Furthermore, the underglycosylation of the MUC1 extracellular domain also results in the exposure of the peptide backbone. Tumor-associated epitopes consisting of both the saccharide and the peptide structures are formed.
By an efficient induction of antibodies specific to the tumor-associated MUC1 antigens, it should be possible to break the tolerance of the immune system against these structures. In order to produce such a humoral immune response, a naı¨ve B cell needs to be stimulated to proliferate and to differentiate into an antibody-secreting plasma cell. To this end, additional stimulation by activated CD4 þ T helper cells is required. The naı¨ve T helper (T H ) cells are activated when their T cell receptor (TCR) binds to the peptide epitope presented by the major histocompatibility complex II (MHC II) on the surface of a antigen-presenting cell (APC). The peptide epitope presented by the APCs had to be generated by proteolytic fragmentation of the extracellular antigen that was internalized via recognition of the B-cell epitope. The protolytically cleaved fragments can then either bind to the MHC class I proteins initiating cytotoxic T-cell activation or bind to the MHC class II proteins generating T helper cell activation. 30 Efforts have been made to synthesize MUC1 tandem repeat glycopeptides that mimic the abberant glycosylated cell surface glycoprotein. These peptides are of interest to develop synthetic vaccines and also to generate monoclonal antibodies for immunotherapy and as diagnostic tools. The tumor-selective MUC1 glycopeptides are only moderately immunogenic, and additional stimulation using a carrier protein, e.g. KLH, or an immunostimulating T H -cell peptide epitope, as for example, a peptide sequence of ovalbumin, is necessary to generate a humoral immune response. 31, 32 During immunization it is also necessary to stimulate the innate immune system, this is done by adding an adjuvant together with the vaccine, for example Freund's adjuvant, or using an adjuvant built into the vaccine, for example Pam 3 Cys which is a ligand to the Toll-like receptors. 33 Examples of synthetic vaccines based on the tumor associated MUC1 glycopeptide epitope conjugated with various immunostimmulants will here be given. 
Synthesis of T N , T, sialyl T N , sialyl T glycosyl amino acid building blocks
Chemical synthesis of glycosylated Fmoc-serine and threonine building blocks for solid phase peptide synthesis still is a demanding task. Most such building blocks are back integrated to the T N -antigen intermediate 12.
By making use of the high reactivity of the 6-and 3-positions of Gal in combination with proper protecting groups, highly selective glycosylations can be performed. T N -antigen was synthesized from acetobromogalactose 34 1 via the corresponding galactal 35 2 and its azidonitration 36 yielding an anomeric mixture of azidonitrate 3, which was subsequently converted to the corresponding a-bromide 4 by treatment with LiBr in acetonitrile. 36 Fmoc-threonine tert-butyl ester, 37 or its serine counterpart (not shown) was then glycosylated with 4 under Koenigs-Knorr conditions [38] [39] [40] [41] providing 5. The azido function was then converted to the corresponding acetamide 6 by thioacetic acid, 42, 43 and the tert-butyl ester was cleaved by TFA in presence of anisole as a scavenger, providing the fully protected T N -antigen building block 7 for further solid phase peptide synthesis (SPS) (Scheme 1).
Synthesis of 2,6-Sialyl T N antigen 40 begins with the preparation of the sialyl donor 11. It has been proven in a number of syntheses 17, 18, 40 that glycosylation reactions with xanthate 44 11 in the presence of a thiophilic activator are superior to the use of other sialic acid donors. Peracetylation of sialic acid 8 gave the fully acetylated intermediate 9, which was benzylated with benzyl bromide/cesium carbonate to give 10 as an anomeric mixture. 45 Treatment of 10 with acetyl chloride followed by treatment with KS(CS)OEt under thermodynamically controlled conditions afforded xanthate 11 as a single anomer. 44 After careful deacetylation of Fmoc-T N antigen-threonine 6, 41,46,47 the resulting product 12 was sialylated selectively in 6-position using xanthate 11 and MeSOTf 48 in an acetonitrile containing solvent at low temperature. At low temperature ( À 65 1C), only the kinetically favored equatorial product is formed due to assistance of the nitrile solvent. [49] [50] [51] Further transformations include peracetylation of 13 and cleavage of the tert-butyl ester 14 to give the Fmoc-glycosyl amino acidbuilding block 15 (Scheme 2). Sialyl-T-antigen is best prepared from intermediate 16, which was glycosylated with 6-O-benzylacetobromogalactose 20. 54 The product 21 was subsequently deacetylated by controlled transesterification in methanol preventing b-elimination. Sialylation of the more reactive equatorial 3 0 -position with sialic xanthate 11 proceeded smoothly, thus providing 23. The benzylidene acetal of 23 was removed under mild acidic 54 conditions. The deblocked hydroxy groups were then acetylated. Removal of the tert-butyl ester provided the Fmoc-Sialyl-T threonine building block 24 in good overall yield (Scheme 4).
The T-antigen intermediate 21 can also be transformed to the 6-Sialyl-Tantigen 52 by selective glycosylation at 6-position of 25. Solvolytic removal of the benzylidene acetal in 21 yielded the acceptor 25 with free OH groups in 4-and 6-position. Due to the intrinsic low reactivity of the axial 4-OH of galactose, a highly regioselective sialylation takes place, again employing xanthate 11 as the donor, providing 26. Removal of the tert-butyl ester gave the Fmoc-6-Sialyl-T-antigen building block 27. It should be noticed that the 4-OH group is left unprotected. Due to the steric hinderance by the sialic acid moiety, it is not necessary to protect the 4-OH group (Scheme 5).
Synthesis of T N , T, sialyl T N , sialyl T glycopeptides and vaccines
The synthesis of glycopeptides can be achieved by different strategies. Glycopeptides can be prepared by direct attachment of saccharides to the completed target peptide (convergent synthesis) or by the use of glycosyl amino acid building blocks incorporated in the stepwise peptide assembly. The use of the convergent approach is limited, since it is suffering from low yields of glycosylations due to reactivity and selectivity problems. Synthesis of O-glycopeptides by Fmoc solid phase peptide synthesis (SPPS) employing glycosylated amino acids is therefore the more general approach. [55] [56] [57] [58] During peptide backbone assembly, the protected glycosylated amino acid building blocks are usually applied. This is because of the liability of the O-glycosidic bond to strong acid treatment. By treatment with bases, O-glycosyl serine/threonine peptides can undergo b-elimination of the O-linked glycans or epimerization at the stereogenic centers. 59 After cleavage of the synthesized peptide from resin, the carbohydrate protecting groups need to be removed under mild conditions. O-Acetyl groups commonly used for protection of the saccharide portion can be readily removed under mild conditions, e.g. using dilute sodium methoxide in methanol 41, 60 or hydrazine hydrate in methanol. 61, 62 Glycopeptides can also be prepared employing an enzymatic approach.
63
MUC1 tandem repeat peptides are normally synthesized according to Fmoc strategy on solid-phase in a stepwise fashion starting with a suitable resin preloaded with the C-terminal amino acid. The choice of resin depends on whether the peptide will be cleaved with intact amino acid side chain protecting groups or with deblocked amino acid side chains. For milder cleavage conditions the trityl resin 64 can be used which is cleavable by 0.1% TFA. Alternatively, a resin with the 2-phenyl-2-trimethylsilyl-ethylester linker (PTMSEL) linker 65 can be applied. This linker is cleavable by TBAF. Another linker is the allylic HYCRON linker, 66 which is cleavable by palladium(0) catalyzed allyl transfer. If the side chain protective groups should be simultaneously removed from the peptide during cleavage from the solid support, Wang resin 67 is most commonly used. It is cleaved with a 95% TFA mixture. The choice of resin is also dependent on whether the peptide sequence starts with amino acids prone to form diketopiperazines, as for example proline and alanine. In such a case, a bulky linker is required like a trityl or the fluoride-labile PTMSEL resin. The glycosylated amino acid building blocks (1.5-2.0 equiv.) are often activated with the more reactive HATU/HOAt 68 and coupled manually, while the other Fmoc amino acids are normally coupled automatically on a peptide synthesizer using 5-20 Scheme 5 Reagents and conditions: i) 80% aq. HOAc; ii) MeSOTf; iii) TFA, anisole, 98%.
equiv. and the HBTU/HOBt reagents. 69 After cleavage from resin and purification by HPLC, the glycopeptides are further deprotected on the glycans and then conjugated to the immune stimulant. Deprotection of the glycans favorably is preformed by first removing the sialic acid benzyl ester by catalytic hydrogenation and subsequent removal of the O-acetyl protective groups by transesterification in methanol with catalytic amounts of NaOMe at pH 9-9.5. 70 2.2.1 Synthesis of MUC1 glycopeptides conjugated to a peptide T-cell epitope. Recently, fully synthetic vaccines consisting of MUC1 tandem repeat glycopeptides mono-di-and triglycosylated with Sialyl-T N and T N side chains and connected to an ovalbumin (OVA 323-339 ) T-cell peptide epitope via a non-immunogenic spacer (28) (29) (30) , were prepared 71 according to the strategy outlined above starting with Wang resin preloaded with Fmoc arginine. The glycosylated Sialyl-T N (15) and T N -amino acid (7) building blocks were used in two-fold excess and coupled with HATU/HOAt. The other amino acids were coupled according to standard protocols (20 equiv. amino acid and HBTU/HOBt) in a peptide synthesizer. After release from resin and purification by preparative reversed phase HPLC, the removal of the protecting groups from the glycans was performed by catalytic hydrogenation of the sialic acid benzyl ester, followed by removal of the O-acetyl protective groups through transesterification in methanol with catalytic amounts of NaOMe at pH 9-9.5. After complete deprotection, the glycopeptide-OVA-vaccine constructs were purified again by preparative reversed phase HPLC and isolated in overall yields (calculated from resin) of 36% (28) 17% (29) and 32% (30) (Scheme 6). These synthetic vaccines were used in combination with complete Freund's adjuvant (CFA) for immunization of transgenic mice (DO11.10) whose T cells express an OVA-specific receptor. High antibody titers specific to the corresponding MUC1 antigens were displayed in one of three mice (mouse 4) immunized with vaccine 28 and in two of three mice (7 and 9) immunized with vaccine 29.
71 None of the mice immunized with the triglycosylated vaccine 30 additionally glycosylated in the immuno dominant PDTR domain generated an immune response. Further immunization of additional 10 mice with this vaccine 30 confirmed that no immune response was induced. However, the antibodies generated from vaccines 28 and 29 were studied in ELISA and microarray binding specificity studies. 72 The antibodies generated from the mono-and diglycosylated MUC1 vaccines 28 and 29 had a very similar binding specificity. It could be concluded that the antibodies were highly specific for glycosylation with Sialyl T N in the HGVT domain of the MUC1 tandem repeat. When the glycan was removed or moved to another position of the tandem repeat sequence, the binding was totally lost. If the required glycosylation with Sialyl-T N in the HGVT region was given, additional glycosylation with T N or Sialyl T N in the PDTR or GSTA region was accepted by the antibody. Glycopeptides consisting of more than one tandem repeat were also recognized.
It could be also concluded that the GSTA part was not important for binding, while removal of the immunodominant PDTR region resulted in a complete loss of binding of the antibodies. The abilities of these antibodies from the vaccines 28 and 29 to recognize cancer tissues or to protect mice against tumors to grow and spread are currently under investigation. (Scheme 6).
Synthesis of MUC1 glycopeptides conjugated to carrier protein.
Vaccines consisting of protein conjugates, as for example BSA or KLH conjugates, are well-established. A few examples based on employing different carrier proteins and conjugation methods will be outlined. MUC1 glycopeptides conjugated through coupling with diethyl squarate, using an alkene-thiol addition reaction, a maleimide-thiol reaction or a glutaraldehyde coupling will be mentioned. Common to all these reactions is that the MUC1 glycopeptide must be deprotected at the peptide side chains and the glycans prior to the conjugation to the carrier protein. One example includes a monoglycosylated Sialyl-T N MUC1 glycopeptide with the same structure as coupled to the OVA T-cell epitope described above, which was conjugated to Tetanus toxoid protein 73 employing diethyl squarate (3,4-diethoxy-3-cyclobutene-1,2-dione) as the coupling reagent. 74 Tetanus toxoid conjugates have been applied to humans in several vaccines with bacterial and viral targets. Therefore, this carrier protein has the potential of an attractive constituent also in a MUC1 glycopeptide vaccine. The MUC1 glycopeptide containing a triethylene glycol spacer 66, 70 terminating in a free amine (31) was prepared according to Fmoc strategy in a similar fashion as described for the OVA-vaccines 28-30. However, in this case a trityl resin was used, in order to avoid diketopiperazine formation at the C-terminal sequence Pro-Ala-(Scheme 7). Employing TFA, the completed glycopeptide was cleaved from the resin and with concomitant removal of the peptide side chain protecting groups. 73 The disaccharide portion was then deprotected by hydrogenation using palladium on charcoal and subsequent deacetylation using NaOMe in methanol to yield the Sialyl T N MUC1 glycopeptide (31) in an overall yield of 61%.
Scheme 7 Synthesis of Sialyl-T N MUC1-T.Tox. protein vaccine.
The (84%) . The squarate monoamide-glycopeptide was coupled to the Tetanus toxoid in aqueous sodium phosphate buffer at pH 9 to furnish vaccine 33 with, on average, 20 glycopeptides conjugated to the protein. 73 Immunolgical evaluation of the vaccine showed that a very strong immune response was induced in all of the 10 mice immunized. Specificity studies through glycopeptide microarray experiments brought to light that the generated antibodies display a similar specificity as the antibodies obtained after immunization with the monoglycosylated Sialyl-T N vaccine 28 exerting a high specificity for Sialyl-T N glycosylation in the HGVT sequence which also is the postion glycosylated in the immunogen. 72 Additional glycosylation with T N or Sialyl-T N in other positions were also recognized. ELISA neutralisation experiments showed that MUC1 glycopeptides with Sialyl-T N or 2,6-Sialyl-T glycans in the HGVT position partially neutralize these serum antibodies, while glycopeptides with T or 2,3-Silayl-T glycosylation in the HGVT position only weakly bind to the antibodies. 73 It can be concluded that very specific antibodies have been elicited by this vaccine. Together with the OVA vaccine 28 the potential of this vaccine 33 will be further elucidated (Scheme 7).
MUC1 vaccines based on Sialyl-T and T glycopeptides have also been prepared. In one example, these glycopeptides were connected to bovine serum albumin (BSA) as the carrier protein via a thioether linkage and a non-immunogenic spacer. 75 Formation of thioethers via a radical-induced addition of thiols to alkenes is considered favourable in comparison to the more common peptide-protein conjugation techniques employing squarates 74 or maleimide 76, 77 linkers, which have the potential to be immunogenic themselves. A 2,3-Sialyl-T MUC1 glycopeptide with a thiol spacer at the N-terminus was prepared starting from trityl resin preloaded with proline. The glycopeptide assembly and the detachment from the resin according to the procedure described above gave the partly protected glycopeptide 34 in 36% yield. Removal of the protective groups was performed to give the thiol glycopeptide 35, which was coupled to olefin-modified BSA in water employing UV-radiation. After dialysis and lyophilization the pure antigen-BSA conjugate 36 was obtained (Scheme 8a).
The reverse thioether formation was also achieved via the synthesis of an allylamide-functionalized T-antigen MUC1 tandem repeat peptide (37) (39% overall yield) and photochemical coupling to BSA carrying a thiol spacer to give 38 (Scheme 8b). 75 These glycopeptide vaccines have not been employed so far in immunization experiments, but it would be interesting to see the outcome of these vaccines (Scheme 8).
Enzymatic approaches have also been used to prepare MUC1 glycopeptide vaccines. One example concerns a 60 mer MUC1 tandem repeat peptide glycosylated with T N and Sialyl-T N glycans which was conjugated to KLH as carrier protein. 78, 79 A MUC1 60 mer peptide consiting of three tandem repeats (39) was prepared through standard Fmoc solid-phase peptide synthesis. After cleavage and purification, the peptide was completely glycosylated with T N monosaccharides (40) in vitro through a concerted action of GalNAc-T2 and GalNAc-T4 glycosyltransferases. These reactions were performed using UDP-GalNAc and N-acetylgalactosaminyl transferases (GalNAc T-2 and GalNAc T-4) in a sodium cacodylate, MnCl 2 and Triton X-100 buffer at pH 7.4 yielding the glycopeptide construct 40 fully glycosylated on all potential glycosylation sites. A part of the glycopeptide material was further sialylated using ST6GalNAc-I, a human a-Nacetylgalactosamine a-2,6-sialyltransferase, in order to produce a MUC1 60 mer with Sialyl-T N (41) glycopeptide vaccines 42 and 43 were administered to Balb/c mice and human MUC1 transgenic mice (MUC1 Tg). Strong immune responses specific to the MUC1 60 mer 15 ST N and T N immungene structures were generated in both series of mice. Serum generated from the T N glycopeptide vaccine 42 reacted strongly with the human breast cancer cell line T47D, which mainly carries T N and some T and Sialyl-T glycans, but weaker with the MCF7 breast cancer cell-line. The non-tumorigenic epithelial cell-line MTSV1-7 which expresses high levels of the core 2 b-1,6-GlcNAc transferase was not recoginized by the sera. The sera generated from the Sialyl-T N glycopeptide vaccine 43 was staining primary breast cancer cells expressing MUC1 and ST N and could not react with the MCF7 breast cancer cell-line. Monoclonal antibodies (5E5) were also generated with the MUC1 60 mer-15 T N vaccine 42 as the immunogen. Antibody specificity studies showed that these antibodies were, in particular, specific to antigen structures glycosylated in the GSTA part of the MUC1 tandem repeat (Scheme 9).
Other examples of vaccines have been prepared consisting of glycan multi-epitope peptides conjugated to KLH as the carrier protein. It was considered attractive to prepare vaccines targeting more than one tumor associated epitope at the same time during the immunization. This was done by combining vaccines targeting different tumor-associated glycans on the peptide backbone, as for example T N , Sialyl T N , T and Sialyl-T structures, or by combining vaccines with various positions of glycosylation at the MUC1 tandem repeat. The problem with immunizations using combined vaccines with different antigens separately conjugated to the carrier protein concerns the risk that increased levels of the used carrier protein may lead to a decreased immunogenicity of the individual antigens. To avoid this disadvantage an approach employing unimolecular multi-epitope vaccines was designed. [80] [81] [82] Hybrid glycan-peptide KLH conjugate vaccines were prepared based on a mixture of tumor associated glycans linked through spacers to a peptide backbone. Both tumor-associated glycolipid glycans like Globo-H, GM2 and glycoprotein glycans like T N , Sialyl T N , T were combined in the vaccine. These hybrid glycan-peptide conjugates were prepared through stepwise coupling of the individual Fmoc protected glycan-spacer amino acid building blocks employing EDC, HOBt, Et 3 N (Scheme 10). The glycosylated spacer amino acid building blocks were prepared by different strategies. T N , Sialyl T N and T linked amino acids 45-47 containig a three-carbon spacer were prepared by coupling of glycan trichloroacetamidates with Fmoc protected hydroxynorleucine benzyl ester in the presence of a Lewis acid, TMSOTf or ZnCl 2 (Scheme 10b). The GM2 and Globo-H amino acid building blocks 48 and 49 containing a five-carbon spacer were prepared by conjugation of Globo-H pentenyl glycoside with protected allyl glycine through olefin cross-metathesis in the presence of a ruthenium catalyst. Reduction of the formed olefin and concomitant removal of the benzyl ester generated the glycosylated amino acid building blocks (Scheme 10a).
After assembly of these buiding blocks, the Boc protecting group was removed from the C-terminal diamine spacer by TFA treatment. Subsequently, introduction of a thiospacer and deprotection of glycan and spacer were carried out employing sodium hydroxide in methanol. The deprotected hybrid glycan-peptide construct 50 was conjugated to KLH which had been functionalized with a maleimide by stirring at room temperature in a pH 6.5-7 phosphate buffer for 4 h. In average 505 hybride glycopeptides consisting of Globo-H, GM2, T N , Sialyl-T N and T glycans were coupled per molecule KLH. The prepared vaccine construct 51 was used for immunisation of mice. Fom ELISA evaluation of the mice sera it was concluded that both IgG and IgM antibodies were generated, which Scheme 10 Methods to prepare glycosylated amino acid mimics; a) through olefin crossmetathesis; b) through coupling of hydroxynorleucine to a glycan trichloroacetimidate in the presence of a Lewis acid.
recognized each individual carbohydrate antigen. Additional FACS analysis showed that MCF-7 breast cancer cells were recognized by the sera, however, exclusively antibodies of short-lived IgM type were responsible for the recognition 81,82 (Scheme 11).
Synthesis of MUC1 glycopeptides conjugated to a build-in adjuvant and T-cell epitope.
Adjuvants typically are immuno stimulants, which consist of characteristic molecular patterns derived from pathogens to which the immune system is commonly pre-exposed. An example of a MUC1 glycopeptide vaccine conjugated to both an immuno adjuvant and T-cell epitope will be described. [83] [84] [85] The adjuvant used, S-[(R)-2,3-dipalmitoyloxy-propyl]-N-palmitoyl-(R)-cysteine (Pam 3 Cys) 86 is a ligand of the Toll-like receptor 2. Through its interaction with the receptor, pro-inflammatory cytokines and chemokines are produced, which stimulate the antigen presenting cells (APCs) that can process and present the immunogenic epitopes contained in the vaccine to the T-cells. The lipopeptide structure Pam 3 Cys also facilitates the formation of liposomes, which serve as efficient vaccine delivery vehicles. The peptide sequence 103-KLFAVWKITYKDT-115 derived from polio virus was included as aT H -cell epitope. The B-cell epitope consisted of a MUC1 decapeptide containing a T N (GalNAc) residue in the immunodominant domain.
The MUC1 glycopeptide was synthesized through solid-phase peptide synthesis applying a Fmoc T N -threonine building block as previously described. A cysteine was attached at the N-terminus prior to cleavage from the resin. The protective groups of the glycan were removed by aqueous hydrazine. The peptide 52 containing the N-terminal cysteine was used for a native chemical ligation (NCL) reaction with the T-cell epitope peptide. Employing a Kenner-Ellmann (sulfonamide) resin 87 preloaded with a glycine, the T-cell epitope peptide 53 containing N-terminal S-acetamidomethyl (Acm) cysteine was obtained by methods of peptide assembly.
After alkylation of the acyl sulfonamide linker, cleavage with benzyl mercaptane and sodium thiophenolate in THF yielded the peptide thioester with protected side chains. After purification, the peptide was treated with TFA cocktail, which removed the amino acid side chain protecting groups and yielded 53. The native chemical ligation between the MUC1 peptide thiol 52 and the T-cell epitope thioester 53 was performed in a phosphate buffer (pH 7.5) in the presence of tris-carboxyethyl phosphine and EDTA and subsequent ultrasonication. The ligation reaction was initiated by addition of 2-sulphanylethyl sulphonate and completed after 2 h as monitored by LC-Ms. After removal of the acetamidomethyl group of the primary ligation product, peptide 54 was obtained in good yield.
Subsequently, a second liposome-mediated NCL was preformed together with the synthesized Pam 3 Cys peptide benzylthio ester 55 thus forming the three-component vaccine 56. The use of liposome mediated native chemical ligation greatly facilitated the formation of the vaccine construct (Scheme 12).The T N MUC1-polio [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] Pam 3 Cys three-component vaccine 56 was incorporated into phospholipid based liposomes and used for immunization of mice. The antibody titers were detected by ELISA using microtiter plates coated with the 11-mer MUC1 glycopeptide conjugated to BSA. A high IgG immune response was detected. According to FACS analysis, these antibodies also showed reactivity against the MUC1 specific breast cancer cell line (MCF-7).
Synthesis of MUC1 glycopeptide dendrimer vaccines.
By employing a multiple-epitope presentation based on a dendrimer, as for example the oligo-lysine core, 88 a carrier-induced immune suppression that can occur during immunization with carrier protein vaccines should be avoided. Vaccines based on multiple antigen presentation could also be favourable for the uptake and presentation of the antigen by antigen presenting cells. Syntheses of MUC1 and MUC4 T N and Sialyl T N glycopeptide dendrimer vaccines have recently been reported. 89, 90 Such vaccines were prepared in both forms, with and without an extra immunostimulating Tetanus toxoid T-cell peptide epitope. 70, 91 In order to separate the B-and T-cell epitope and the di-lysyl lysine core from each other, a triethylene glycol spacer amino acid was incorporated in between them.
The Sialyl T N MUC1 glycopeptide 57 and the Tetanus toxoid T-cell epitope 58 with a triethylene glycol spacer at the C-terminus were prepared by Fmoc-strategy on solid-phase. Starting with aminomethyl-polystyrene resin (AMPS) functionalized with a Fmoc-prolyl HYCRON linker 66 and a Fmoc-valine loaded on a triethylene glycol spacer, solid-phase syntheses of the glycopeptide and the TTox peptide were performed (Scheme 13). Palladium(0)-catalyzed cleavage of the allylic HYCRON linker gave the MUC1 glycopeptide 57 and the N-benzyloxycarbonyl protected TTox peptide 58 in overall yields of 36% and 42%, respectively (Scheme 13). 90 The di-lysyl lysine core for multiple antigen presentation was prepared starting from an amide coupling between lysine tert-butyl ester 59 and dibenzyloxycarbonyl (Z) lysine (36% yield). The generated Z-protected dilysyl lysine ester core 60 was then hydrogenated to give the deprotected amine core 61 in 96% yield (Scheme 14a).
C-S-K-K-K-K-G-K-L-F-A-V-W-K-I-T-Y-K-D-T-G-C-T-S-A-P-D-T-R-P-
For preparation of dendrimer constructs, fragment condensation of the MUC1 Sialyl T N glycopeptide 57 (8 equiv.) to the di-lysyl lysine core 61 was performed employing HATU/HOAt and N-methyl morpholine for activation and furnished the MUC1 glycopeptide dendrimer construct in 65% yield. Acidolytic removal of the peptide side chain protecting groups and glycan deprotection by catalytic hydrogenation of the sialic benzyl esters and deacetylation by sodium methoxide in methanol produced dendrimer vaccine 90 62 (Scheme 14b). In a similar fashion the glycopeptide dendrimer vaccine also including the TTox T-cell epitope peptide was prepared (Scheme 14c). After condensation of the TTox peptide 58 (8 equiv.) to the di-lysyl-lysine core to give 63, the benzyloxycarbonyl groups were hydrogenolyzed. Simultaneous coupling of the MUC1 glycopeptide 57 (8 equiv.) and subsequent removal of peptide and glycan protecting groups gave the dendrimer vaccine 64. 90 The synthetic dendrimer vaccines are under investigation in ongoing immunization studies (Scheme 14).
N-Glycopeptide vaccines of HIV-1 envelope glycoproteins gp120 and gp41
The HIV-1 envelope gp120 and gp41 glycoproteins 8 are interesting targets for the development of vaccines based on glycopeptides. The proteins are heavily N-glycosylated. The glycans mask the underlying protein domains forming a ''glycan shield'' that can evade immune recognition and proteolysis. The HIV glycans also are involved in the HIV infection and transmission processes. 92, 93 For example, the high-mannose residues on the gp120 glycoprotein function as ligands for the dendritic cell receptor DC-SIGN. Through DC-SIGN-mediated binding and uptake into the dendritic cells, transmission of HIV-1 from dendritic cells to CD4 helper Tlymphocytes can occur. 94 The outer envelope glycoprotein gp120 is glycosylated with N-glycans on 24 sites, 13 of those are occupied by N-glycans of complex type and 11 sites are linked to high-mannose or hybride-type Nglycans. 95 The gp120 N-glycans are oriented in distinct oligosaccharide cluster domains, one domain consisting solely of high-mannose type and another consisting of complex type N-glycans. 96 The inner envelope glycoprotein gp41 is less heavily glycosylated. It contains 4 N-glycosylation sites. 97 The high-mannose N-glycans on gp120 and gp41 have been considered primary targets for HIV vaccine development. Reasons for this are that N-glycans of complex type are very diverse and displayed on the extracellular glycoproteins of the host. Therefore, it will be difficult to break the self-tolerance of the immune system, and the risk of side effects by treatment with such vaccines is high. With high mannose structures as targets the primary infection of the host T-cells should be hindered. In addition, the high-mannose-specific monoclonal antibody 2G12 is one of few antibodies that was able to neutralize HIV-1 in vitro and in vivo (by passive immunization). 98, 99 The binding epitope of the 2G12 monoclonal antibody has been extensively studied. It was concluded that this epitope is large and consists of a mannose cluster domain including the gp120 high-mannose glycosylation sites Asn 295 , Asn 332 , Asn 392 . The glycosylation sites Asn 339 , Asn 386 and Asn 448 also seem to be involved. [99] [100] [101] Attempts to develop a vaccine mimicking this binding epitope by linking of high-mannose residues to a cyclic peptide scaffold and conjugation of the glycopeptide construct to an immune carrier were undertaken. 102 Glycopeptides consisting of a part or the whole variable V3 domain of HIV gp120 have also been prepared. 103, 104 In addition, a 34-mer glycopeptide (C34) from the C-terminal region (628-661) of gp41 with a high-mannose N-glycan at the conserved glycosylation site Asn 637 was synthesized. 105 The gp120 and gp41 N-glycopeptides were prepared by a convergent approach attaching the glycan to the peptide backbone by condensation of the corresponding glycosylamines to aspartyl side chains 106 of the peptides or by a chemoenzymatic approaches employing an endoglycosidase. 107 
Synthesis of HIV gp120 glycopeptides and vaccines through condensation of glycosylamines to aspartic side chains
In order to prepare HIV gp120 N-glycopeptides consisting of a part of the gp120 V3 loop or a cyclic scaffold to mimic the high-mannose cluster domain, one or several high-mannose Man 9 GlcNAc 2 oligosaccharides were transformed to the corresponding glycosylamines 108, 109 and coupled to the pre-formed peptide backbone. In these convergent approaches the protected peptide containing an unprotected aspartate had been synthesized and coupled with the glycosylamine employing peptide coupling reagents in order to form the asparagine amide bond. 106 The glycosylamines employed in the coupling were obtained by treatment of the unprotected oligosaccharide with a saturated solution of ammonium hydrogen carbonate (Kochetkov). In both cases, the synthesis starts from a common trisaccharide precursor 65. Employing the simultaneous mannosylation, the trisaccharide acceptor 65 with a free hydroxyl group in 3-position of the mannose residue was glycosylated with a mannose thioglycoside donor 66 activated through a radical cation. 110 Selective benzylidene acetal opening gave the tetrasaccharide acceptor 68 with a free 6-OH group. A second mannose thioglycoside donor 69 was employed to generate the pentasaccharide 70.
The O-benzoyl protecting groups on the terminal mannose residues were removed by transesterification with NaOMe in methanol to get three free hydroxy acceptor sites (71) . Trimannosylation again using mannose thioglycoside donors 66 under Sinay¨radical conditions gave the octasaccharide 72 in a good yield. Again repeated debenzoylation and trimannosylation afforded the protected Man 9 Glc 2 high mannose oligosaccharide 103 
(Scheme 15).
Employing the block approach, the trisaccharide acceptor ManGlcNAc 2 65 was reacted with a mannose trisaccharide thioglycoside donor 82 activated by MeOTf to give the hexasaccharide 83. After reductive benzylidene acetal ring opening, the formed hexasaccharide acceptor 84 was glycosylated with a pentasaccharide thioglycoside donor 81 after Sinay¨radical cation activation 110 to give the protected Man 9 Glc 2 high mannose oligosaccharide 85 in 63% yield (Scheme 16). The high mannose oligosaccharides 74 and 85 formed by the simultaneous or block glycosylation approach were then deprotected by removal of the O-acetyl, O-TBS and O-benzyl protecting groups to yield 86. The free oligosaccharide was treated with a saturated solution of ammonium hydrogen carbonate (Kochetkov amination) 108 to form the glycosylamine 87 ready for convergent coupling to the peptide backbone (Scheme 17).
3.1.2 Synthesis of N-glycopeptides of the HIV gp120 V3 loop through aspartic peptide-glycosylamine condensation. In order to prepare a highmannose glycopeptide consisting of a part of the HIV gp120 V3 loop, a peptide with the sequence gp120 216-235 was synthesized through solid-phase peptide synthesis according to Fmoc-strategy. 103 After cleavage from resin and simultaneous removal of the amino acid protecting groups, convergent coupling of the high-mannose glycosylamine 87 to Asp 332 of the peptide backbone was performed employing HATU, HOAt and DIPEA in DMSO.
Since the peptide sequence also contained a reactive lysine residue this needed to be protected during the amide coupling. After the coupling, the IvDde group was removed and the target high-mannose HIV gp120 [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] glycopeptide 89 was formed. This peptide has so far not been employed in conjugation reaction to generate a vaccine 103 (Scheme 18).
3.1.3 Synthesis of a vaccine based on a mimic of the high-mannose cluster domain of HIV gp120. An alternative approach to vaccines included the preparation of a non-natural cyclic peptide scaffold, which after glycosylation should mimic the high-mannose cluster domain of HIV gp120. 102 This glycan cluster region was considered the binding epitope of the monoclonal antibody 2G12 known to broadly neutralize HIV gp120 structures. Glycopeptides consisting of mono-, di-or trimeric glyco clusters were prepared. The dimeric cluster glycopeptide was conjugated to an immunostimulant consisting of the purified outer membrane protein complex (OMPC) 111 derived from Neisseria Meningidis. The conjugate was used for immunization of guinea pigs and macaque monkeys. Starting from trityl resin preloaded with proline two 14-mer cyclic peptides 90 and 91 were prepared through solid-phase synthesis (Scheme 19).
These peptides contained two or three aspartate residues, a protected cysteine for later conjugation and two D-Pro-L-Pro sequences in order to promote b-turn conformations at both ends of the macrocycle. 112 After peptide assembly, the peptides were detached from the resin. Subsequent macrocyclization through an amide coupling employing HATU and DIPEA gave 92 and 93. The aspartate tert-butyl esters were cleaved with TFA and the di-ord tri-aspartate macrocycles 94 and 95 were employed in a simultaneous coupling 106 with the Man 9 GlcNAc 2 glycosylamine 87. The di-and trimer-cluster glycol-conjugated peptides 96 and 99 were isolated in 70 % and 45 % respectively. 102 In addition, the monomeric glycan-peptide conjugate was isolated as a minor product. The synthesized cluster glycopeptides were employed in binding studies of the monoclonal antibody 2G12 using the surface plasmon resonance technology (SPR). It was shown that the di-and tri-mer cluster glycopeptides were recognized, but not the monoglycoconjugate. The di-valent glycopeptide 96 was selected for additional conjugation to the OMPC carrier protein. The tert-butyl-disulfide protection of the cysteine within the macrocycle was reduced by treatment with excess of MESNa to give the free thiol 97. The thiol-containing conjugate 97 was coupled to the OMPC carrier protein, functionalized with maleimido groups. Unreacted maleimido groups had been capped with 2-sulphanylethanol. The loading of glycopeptides 97 on the OMPC carrier was estimated to about 2000-3000 mol peptide per mol protein (Scheme 19). Immunization of guinea pigs and macaque monkeys with the synthesized high-mannose di-mer glycopeptide-OMPC vaccine 98 showed that an immune response was induced in both cases and induced antibodies which recognized the mono and di-valent cluster glycopeptides with a similar binding affinity. 102, 113 It was also found that gp160, a biosynthetic precursor of gp120 and gp41, was not recognized by the thus generated antibodies. The sera were also tested in HIV neutralization experiments. However, specific neutralization was not observed in any group. It was concluded that an immune response specific to the immunogen was induced, but the Scheme 19 Synthesis of a high-mannose cluster glycopeptide mimotope of HIV gp120.
presentation of the immunogen in these vaccines was insufficient to mimic the native structure of the HIV gp120 protein. 102, 113 3.2 Chemoenzymatic synthesis of a HIV gp120 V3 domain N-glycopeptide
The third variable (V3) domain of HIV-1 gp120 is an important target for the development of HIV-1 vaccines. 114 This domain has three conserved Nglycosylation sites. In order to study how N-glycosylation affects the conformation, immunogenicity and proteolytic stability of these peptides, a cyclic N-glycopeptide consisting of the V3-domain and the N-glycan core pentasaccharide was synthesized. 104 A chemoenzymatic approach was used employing endoglycosidase A (endo A) 107 instead of a transglycosylase. 115 Endoglycosidases normally exert hydrolytic activity cleaving the b-(1-4) glycosidic bond within the chitobiose fragment of the pentasaccharide core. However, it has been found that they also can promote transglycosylation. Thus, a large oligosaccharide can be attached to a GlcNAc-containing peptide or protein in one step via the endoglycosidase-catalyzed transglycosylation reaction. The coupling efficacy usually is low, because problems caused by product hydrolysis can occur. Using synthetic oxazoline oligosaccharides as donors, which mimic the 1,2-oxazolinium ion intermediate, the coupling efficacy has been distinctly improved. 116 The synthesis of the HIV gp120 V3 domain containing 47 amino acids and two N-linked core pentasaccharides will exemplify the potential of this approach. 116 3.2.1 Synthesis of the oxazoline tetrasaccharide donor. The oxazoline tetrasaccharide donor 107 was prepared via activation of the peracetylated core tetrasaccharide 106, 116 which was obtained through coupling of a-mannose to the Manb1,4GlcN disaccharide 104. Synthesis of the disaccharide 102 was achieved through b-glycosylation using glucosyl thioglycoside 100 and N-phthaloylglucosmine derivative 101. The glucoside was inverted to a b-mannoside by forming the 2-O-triflate and nucleophilic substitution using tetrabutylammonium benzoate to give 103. After removal of the p-methoxybenzyl protecting group in 3 0 -positon, selective benzylidene acetal opening gave the 3 0 ,6 0 -diol 104. Reaction with the mannose trichloroacetimidate 117 105 activated by TMSOTf formed the a-mannosylated product 106. Removal of the phthalimido group with ethylene diamine followed by treatment with acetic anhydride, hydrogenolytic removal of the benzyl groups, and acetylation gave the peracetylated tetrasaccharide. The oxazoline product was formed by treatment with TMS-Br/BF 3 Et 2 O. 116 Deacetylation with sodium methoxide in methanol afforded the tetrasaccharide oxazoline 107 used in the endoglycosidase-catalyzed glycopeptide coupling 104 (Scheme 20).
Synthesis of
Fmoc-glucosamine asparagine building blocks. The GlcNAc-Asn building block 113 was synthesized from N-acetyl glucosamine 108, which was treated with acetyl chloride to yield the peracetylated a-chloride 109. Phase-transfer catalyzed anomeric substitution employing NaN 3 gave the b-glycosyl azide 118,119 110, which was hydrogenolyzed to give glycosyl amine 116, [118] [119] [120] 111. After coupling 120, 121 with Fmoc-protected tert-butyl aspartate and acidolytic removal of the tert-butyl ester, the glycosylated amino acid building block 113 was obtained (Scheme 21). 104 3.2.3 Synthesis of a cyclic V3 Loop glycopeptide and endo a glycosidasecatalyzed coupling using the man 3 GlcNAc oxazoline donor. A cyclic 47-mer glycopeptide was prepared corresponding to the amino acid residues 290-336 of HIV gp120, with two GlcNAc residues in the conserved N-glycosylation sites N 295 and N 332 . 104 The glycopeptide was assembled by solid phase synthesis according to Fmoc strategy using a PAL-PEG-polystyrene resin. The glycosylated amino acid Fmoc-(OAc 3 GlcNAc)-Asn-OH 113 was activated with HATU and DIPEA. The two cysteines later used for cyclization of the peptide were S-protected with acetamidomethyl (Acm) groups, which are relatively stable to both acidic and basic conditions. After glycopeptide assembly the peptide was detached from the resin using a TFA cleavage cocktail. The crude peptide was treated with 5% aqueous hydrazine in order to remove the O-acetyl groups from the glycan. Purification by RP-HPLC gave the linear glycopeptide 114 in a total yield of 16%. Treatment of the glycopeptide with iodine in 10% acetic acid deprotected the cysteines and directly resulted in cyclization. Endo A 122 -catalyzed transglycosylation of the Man 3 GlcNAc oxazoline donor 107 to the cyclic GlcNAc peptide (3:1 donor/acceptor ratio, phosphate buffer pH 6.5) was completed after two hours to afford the peptide 115 diglycosylated with the pentasaccharide core in 86% yield 104 (Scheme 22) . Due to the high efficiency of the transglycosylation no enzymatic hydrolysis was observed.
Chemoenzymatic synthesis of a C34 glycopeptide from HIV-1 gp41
The C34 region (amino acids 628-661) of HIV-1 envelope glycoprotein gp41 123 is a part of the C-terminal domain and includes a conserved N-glycosylation site at Asn 637 . This sequence can form a six-helix bundle together with the N-terminal peptide N 36 of gp41. The six-helix bundles of gp41 are involved in the virus-host membrane fusion. 124 A non-glycosylated peptide of the C34 region was found to be a potent inhibitor of HIV infection. 125, 126 Therefore, it was interesting to synthesize a glycosylated version of the C34 peptide in order to mimic the natural C-terminal region with N-glycosylation at Asn 637 . A C34 peptide was prepared which contains a high-mannose glycan at Asn 637 (118) . This glycopeptide was employed in a cell-fusion inhibition assay and in a helix-bundle formation study together with the N 36 peptide. It was also considered an interesting component of an HIV gp41 vaccine. The C34 high-mannose glycopeptide 118 was prepared by a chemoenzymatic approach applying the endoglycosidase A 105 (endo-A). In contrast to the chemoenzymatic approach employing the more reactive oxazoline donor as described above, an asparagine building block glycosylated with a high mannose side chain 117 was used (Scheme 23).
The GlcNAc-C34 glycopeptide 116 was prepared by solid-phase synthesis according the methods described for the HIV gp120 glycopeptide outlined above. The Man 9 GlcNAc 2 -asparagine 117 had been isolated from soybean flour. 127 Transglycosylation reaction between the Man 9 GlcNAc 2 -Asn 117 and the GlcNAc-C34 glycopeptide 116 using the endo-A enzyme in a phosphate buffer (pH 6.6) containing 30% dimethyl sulfoxide (DMSO) generated the high-mannose-C34 glycopeptide (M9-C34) 118 in a yield of 11%. 128 The inhibitory activity of the synthesized glycopeptide against HIV infection was determined in a cell-fusion assay. It turned out that the glycosylation of the C34 with a native N-glycan as the high-mannose saccharide resulted in a moderate decrease in the anti-HIV activity compared with the non-glycosylated C34 peptide. However the high-mannose C34 glycopeptide is expected to have a higher solubility under physiological conditions and a stability against protease digestion in vivo. Studies of the helix-bundle formation ability by circular dichroism (CD) analysis applying a thermal gradient showed that the high-mannose glycosylation disrupted the N 36 -C34 six-helix bundle formation. 105 Natural HIV gp41 is N-glycosylated. Destabilization of the N 36 -C34 six-helix bundle occurs during HIV infection. An immunization with a vaccine consisting of the destabilized N36-glyco-C34 six-helix bundle is considered interesting for further exploratory investigations.
Conclusions
In contrast to vaccines directed against bacteria, vaccines which should target viral structures or tumor cells need to represent pathological cell surface structures of multicellular organisms. Almost all proteins of the outer cell membrane of multicellular organisms are glycosylated. Therefore, glycopeptide structures of viral envelope glycoproteins and of tumor-associated membrane glycoproteins are promising antigens for the development of antiviral and antitumor vaccines. Examples given in this chapter demonstrate that efficient chemical methodologies for the synthesis of complex glycopeptide antigens have been developed during the past decades. In addition, techniques have been elaborated which allow for an efficient coupling of these glycopeptide antigens to immunostimulating components, e. g. T cell epitope peptides or Toll-like receptor ligands, or carrier proteins to furnish synthetic vaccines. Immunizations using such vaccines induced immune responses of high structure selectivity in vitro and in cell culture assays. However, sufficient anti-viral efficiency in vivo and distinct differentiation between tumor cells and normal cells in tissues still have to be demonstrated prior to an application of vaccines based on glycopeptides in therapy.
